CDC Website CDC Website

To Join the NPIN community or

Home » HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01 Clinical Trial Not Allowed)

HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between drug resistance mutations present in minority variant viral populations and treatment outcomes, and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

Funding Organization
Funding Category
Locations
National
Eligible Organizations
Number of Awards Given
3 to 6 awards.
Award Amount Notes
NIAID intends to commit $2.4 million in FY 2019 to fund 3 to 6 awards.
Letter of Intent Date
11/5/18
Application Due Date
12/5/18
Project Start Date
7/1/19
Application Contact
Ann
W
Devine
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
240-669-2988
adevine@niaid.nih.gov
Technical Contact
Keith
Crawford, R.Ph., Ph.D.
Program Officer
keith.crawford@nih.gov
240-669-2816
Fund Duration
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Subjects
Audiences
Focus Area

Fund Number: 

5398

Fund ID: 

RFA-AI-18-029

Last Updated: 

7/26/18